Table 1 Selected tissue-agnostic drugs in clinical development

From: Tissue-agnostic cancer drug pipeline grows, despite doubts

Agent Company Target Indication Status
Pembrolizumab Merck & Co. PD1 MSI-H (MMR-deficient) solid tumours Approved
Larotrectinib Loxo Oncology, Bayer TRK Solid tumours with NTRK fusions NDA
Entrectinib Ignyta, Roche TRK, ALK, ROS1 Solid tumours with NTRK fusions Phase II
Merestinib Eli Lilly MET, TRK Solid tumours with NTRK rearrangements Phase II
Atezolizumab Genentech/Roche PDL1 Solid tumours with MSI-H, high mutation burden or alterations in DNA proofreading genes Phase II
TPX-0005 TP Therapeutics TRK, ALK, ROS1 Solid tumours with NTRK, ALK and ROS1 rearrangements Phase I/II
LOXO-195 Loxo Oncology TRK Solid tumours with NTRK fusions, including those resistant to larotrectinib Phase I/II
LOXO-292 Loxo Oncology RET Solid tumours with RET rearrangements Phase I
RXDX-105 Ignyta, Roche RET Solid tumours with RET fusions Phase I
LY3300054 Eli Lilly PDL1 Monotherapy in MSI-H solid tumours; various combination criteria Phase I
PLX8394 Plexxikon/Daiichi Sankyo Mutant BRAF and wild-type CRAF Solid tumours with BRAF mutation Phase I/IIa
PLX9486 Plexxikon KIT Solid tumours with KIT mutations Phase I/II
  1. Tissue-agnostic indications contingent on trial data. MMR, mismatch repair; MSI-H, microsatellite instability-high; NDA, new drug application; PD1, programmed cell death protein 1; PDL1, PD1 ligand 1.
PowerPoint slide